Research
Metabolic adaptation
There was no significant change in hepatic insulin sensitivity after 6 weeks of rifaximin treatment (35.2 [15.3-51.7]% vs. 30.0 [10.8-50.5]%, P = 0.47).
Rifaximin does not appear to enhance insulin sensitivity in NASH patients.
StrongRefutesmedium confidence
no differences were seen in hepatic insulin sensitivity (35.2 [15.3-51.7]% vs. 30.0 [10.8-50.5]%, P = 0.47).
Why this rating
Based on study design from abstract.
Source
Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study
Jeremy Cobbold et al. · Hepatology Research · 2017
other · n=15Cited 49×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →